drugset
drugset / Trial / NCT00898716

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

NCT00898716 ↗

Phase 1 Completed 15 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical study is to establish the maximum tolerated dose of BMS-754807 when administered orally on a once daily schedule in subjects with solid tumors.

Timeline

Start
2009-09
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-754807 Small molecule 20 mg Oral
Subject BMS-754807 Small molecule 30 mg Oral
Subject BMS-754807 Small molecule 50 mg Oral
Subject BMS-754807 Small molecule 70 mg Oral
Subject BMS-754807 Small molecule 100 mg Oral
Subject BMS-754807 Small molecule 130 mg Oral
Subject BMS-754807 Small molecule 160 mg Oral
Subject BMS-754807 Small molecule 200 mg Oral

Indications

neoplasm